Apsara Biotech Research provides in-depth research on publicly traded stocks in the biotechnology sector. We pride ourselves on conducting high quality research for our clients and the public markets. Apsara is not affiliated with a broker-dealer and does not underwrite public offerings or provide investment banking services to the companies that it researches. Therefore, the research coverage provided in our reports are not influenced by the prospect of future investment banking and underwriting fee revenue. Instead, Apsara and its contributors hold long and short positions in the stocks that we write about. Our research commentary is supported by our genuine opinions about the securities covered, rather than a motivation to derive future fee revenue from the subject companies. We hope that you find our approach to biotechnology sector research refreshing, original and accurate. Our research director is Yang Yu and can be reached at firstname.lastname@example.org
Over 17 years of experience in the biopharmaceutical industry, having served in a number of management roles encompassing business development, intellectual property, strategic planning, pre-marketing and communication. As Chief Business Officer he is responsible for developing business alliances, license arrangements, and partnering opportunities with pharmaceutical companies and government agencies. Before joining Immunovaccine, Frederic spent 14 years at Medicago serving in many roles of increasing responsibility and most recently as Vice President of Business development and Strategic Planning. He has been an integral part of Medicago’s success including securing more than $300M in non-dilutive funding in revenues and future milestones from licensing agreements and government contracts and the $357M deal acquisition by Mitsubishi Pharma in 2013.
He also serves as the second Vice-Chair of the Vaccine Industry Committee of Biotech Canada. Prior to Medicago, he was licensing manager at the University Paris VII-Denis Diderot, one of the largest science and medical University in France. He has a B.Sc. degree in Biology and a Master degree in Management from the University of Angers (France).
I am a personal investor and an attorney. I have extensive experience in the consumer credit arena as well as commercial real estate as an investor and a lender. I co-manage a commercial, hard money mortgage fund and also have experience with the Food, Drug & Cosmetic Act.
Bill Douglass is an award-winning writer and futurist, published in The Economist magazine and elsewhere. He is principal at Gotham Communications, LLC, a boutique communications agency, representing a variety of public and venture-backed private companies as well as alternative investment firms. He made his first stock market investment at age 14; current investment interests include life sciences, robotics, energy, technology, and media. His investment philosophy is informed by a global perspective, having lived on four continents and worked in or otherwise traveled to over 60 countries. He is reachable at email@example.com and on Twitter at @billdouglass.
I am starting to invest in small-cap pharmaceutical stocks, and maintain my own portfolio. I am mostly learning about upcoming newer drugs and technologies, while following up with catalysts.